ABDOMINAL OBESITY IN ARTERIAL HYPERTENSION: ATHEROGENIC ALTERATIONS IN LIPID TRANSPORT SYSTEMS AND CARBOHYDRATES METABOLISM

The comparative analysis of CHD risk factors which are known metabolic syndrome components was conducted in groups of patients with arterial hypertension (AH) combined with abdominal obesity (AO), in hypertensive subjects with normal body mass index, and in those with AH, AO and glucose intolerance. The combination of AH with AO was coupled with higher SBP and DBP, and with more pronounced atherogenic shifts in lipoprotein profile: elevated levels of triglycerides, total cholesterol, apo B and apoB/AI ratio. The magnitude of these parameters was closed to that in group with AH, AO and glucose intolerance; hyperlipidemia in the last group was aggravated by decreased HDL cholesterol level. Patients with AH and AO had significantly higher blood insulin level and lower glucose/insulin ratio than subjects with AH only. These results might indicate the existence of latent insulin resistance in hypertensive patients with abdominal (visceral) obesity. Global CHD risk for these patients appeared to be higher than in subjects with AH only. 

1. Перова Н.В., Мамедов М.Н., Метельская В.А. Кластер факторов риска сердечно-сосудистых заболеваний: метаболический синдром. // Междунар. мед. журнал. 1999; № 2:21-24.

2. Ратникова Л.А., Метельская В.А., Мамедов М.Н. и др. Связь между параметрами гемостаза и проявления миметаболического синдрома у мужчин с мягкой и умеренной гипертонией // Тер. Архив. 2000; № 9: 13-16.

3. Соколов Е.И. Сахарный диабет и атеросклероз. / М., Наука, 1994, с.404.

4. Assmann G., Gullen P., Schulte H. The Munster heart study (PROCAM). // Eur. Heart J. 1998; 19 (Suppl. A):A2-A11.

5. Bjontorp P. Abdominal obesity and risk. // Clin. Exper. Hyper.- Theory and Practice 1990; A 12 (5): 783-794.

6. Caro J.F. Insulin resistance in obese and nonobese men. // J. Clin. Endocrinol. Metab. 1991; 73:691-695.

7. Coronary heart disease: reducing the risk. The scientific background for primary and secondary prevention of coronary heart disease. A worldwide view. International Atherosclerosis Society. // Nutr. Metab. Cardiovasc.Dis. 1998; 8:205-271.

8. De Fronzo R.A., Ferranini E. Insulin resistance: a multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia and atherosclerotic disease. // Diabetes Care. 1991;14:173-194.

9. Ducimetiera P., Eschwege E., Papod L. et al. Relationship of plasma insulin levels to the incidence of myocardial infarction and coronary heart disease mortality in a middle-aged population. // Diabetologia. 1980; 19:205-210.

10. Ferrannini E., Barrett E. J. et al. Effect of fatty acids on glucose production and utilization in men. // J. Clin. Invest. 1983; 72:1737-1745.

11. Juhan-Vague I., Thompson S.H., Jespersen J. Involvement of the hemostasis system in the insulin resistance syndrome. A study of 1500 patients with angina pectoris. The ECAT Angina Pectoris Study Group. // Arterioscler. Thromb. 1993; 13: 1865-1873.

12. Mansfield M., Heywood D., Grant P. Sex differences in coagulation and fibrinolysis in white subjects with non-insulin-dependent diabetes mellitus. // Arterioscler. Thromb. 1996; 16: 160-164.

13. Metelskaya V., Serdyuk A., Mamedov M., Perova N., Oganov R. Insulin resistance markers for coronary heart disease high risk subjects selection. // In: Advances in lipoprotein and Atherosclerosis Research, Diagnostics and Treatment. Proc.9th Intern. Dresden Lipid Symposium. Fischer G.(ed). 1997:192-195.

14. Peiris A.N. Struve M.F. et al. Glucose metabolism in obesity. Influence of body fat distribution. // J. Clin.Invest.1988; 67:760-767.

15. Prevention of coronary heart disease in clinical practice. Recommendations of the second joint Task Force of European and other societies on coronary Prevention. // Eur. Heart J. 1998; 19:1434-1503.

16. Rocchini A.P. Role of obesity the association of insulin resistance and salt sensitivity of blood pressure. // Nutr. Metab. Cardiovasc. Dis. 1997; 7:132-137.

17. Tiengo A., Avogaro P., Prato S. Pathogenesis and therapy of plurimetabolic syndrome. // Nutr. Metab. Cardiovasc. Dis. 1996; 6,186-192.